oral brain-penetrant SOS1:KRASG12C PPI inhibitor
efficacy in MIA PaCa-2 tumor mouse xenograft model
from literature starting point and opt
J. Med. Chem.
Mirati Therapeutics, San Diego, CA
Context. MRTX0902 (Mirati Therapeutics) is an oral brain penetrating SOS1:KRAS protein-protein interaction inhibitor. Since the first report of the druggability of the KRASG12C mutant, KRAS has been a hotly…